Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03853317 · ClinicalTrials.gov registry record · Phase 2
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
A Phase 2 study, sponsored by ImmunityBio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03853317: Clinical Trial Phase 2 study, sponsored by ImmunityBio.
NCT03853317 is a Phase 2 study that was terminated before completion, run by ImmunityBio. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03853317, a Phase 2 study, was terminated before completion, sponsored by ImmunityBio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
Phase 2, single-arm study to evaluate combination therapy of avelumab, haNK and N-803 in patients with Merkel Cell Carcinoma who have progressed on or after checkpoint inhibitor therapy as assessed by ORR. Patients will receive treatment for a maximum of two years.
Primary Outcome
The safety of the combination treatment of avelumab, haNK, and N-803 in subjects with MCC that has progressed on or after checkpoint inhibitor therapy
Interventions
- BIOLOGICAL Avelumab
- BIOLOGICAL N-803
- BIOLOGICAL haNK™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-02-19 |
| Est. Completion | 2022-09-19 |
| Phase | Phase 2 |
Why NCT03853317 stopped before completion
NCT03853317 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which Avelumab is the first listed.
NCT03853317 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03853317 about?
NCT03853317 is a clinical study titled "QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy". Phase 2, single-arm study to evaluate combination therapy of avelumab, haNK and N-803 in patients with Merkel Cell Carcinoma who have progressed on or after checkpoint inhibitor therapy as assessed by ORR. Patients will receive treatment for a maximum of two years.
What is the current status of trial NCT03853317?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-02-19. Estimated completion is 2022-09-19.
What interventions are being tested in trial NCT03853317?
The interventions under investigation include: Avelumab (BIOLOGICAL), N-803 (BIOLOGICAL), haNK™ (BIOLOGICAL).
Who is sponsoring clinical trial NCT03853317?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03853317's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI